Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double-Blind Placebo-Controlled Multicenter Study
This multisite, randomized double-blind study investigated targeted nalmefene in reducing heavy drinking.
Alcohol Clin Exp Res. 2007 Apr 19
This multisite, randomized double-blind study investigated targeted nalmefene in reducing heavy drinking. Specialized alcohol treatment centers and private general practices enrolled 403 subjects (328 men, 75 women). Subjects were instructed to take nalmefene 10 to 40 mg (n=242) or placebo (n=161) when they believed drinking to be imminent. After 28 weeks, 57 subjects from the nalmefene group continued into a 24-week randomized withdrawal extension. Concomitant psychosocial intervention was minimal and no treatment goals were imposed.
Nalmefene appears to be effective and safe in reducing heavy drinking, even when accompanied by minimal psychosocial support.
Keywords: Alcohol drinking, Medicine, Nalmefene, Alcoholism, Drug Therapy, Rehabilitation
Avain-/asiasanat: alkoholi, lääketiede, nalmefeeni, alkoholiriippuvuus, alkoholiriippuvuuden hoito, kuntoutus